Statera Revenue and Competitors

Claim your profile

Denver, CO USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Statera's estimated annual revenue is currently $11M per year.(i)
  • Statera's estimated revenue per employee is $145,000

Employee Data

  • Statera has 76 Employees.(i)
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$85M469-2%N/AN/A
#2
$2.2M15N/AN/AN/A
#3
$3M21N/AN/AN/A
#4
$17.4M120N/AN/AN/A
#5
$2.9M29N/AN/AN/A
#6
N/A0N/A$13.1MN/A
#7
$0.5M15N/A$4.3MN/A
#8
$446.5M153710%$60.7MN/A
#9
$4M4621%$20.5MN/A
#10
$0.6M8N/AN/AN/A

Statêra, a Navint company, is a full-service Salesforce focused consultancy, specializing in Sales & Service Cloud, Quote-to-Cash, and Salesforce Platform and AppExchange solutions that drive change for our clients. In our 19 years in business we have completed over 2,000 successful engagements by delivering the right solutions, delighting our clients, supporting our communities, and by providing interesting and productive careers for our people. Our methods focus on process over platform and talent over technology.

keywords:N/A

N/A

Total Funding

76

Number of Employees

$11M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Statera News

2022-04-20 - Why Are Statera Biopharma Shares Surging Today - Benzinga

Additionally, Statera will receive milestone-based payments. Potential indication payments will include asthma, multiple sclerosis, HIV, and...

2022-04-20 - Statera Biopharma Shares Rise 100%; Company in Rights Deal With Immune Therapeutics

By Stephen Nakrosis. Shares of Statera Biopharma Inc. more than doubled in price on Nasdaq Thursday, a day after the company said it entered...

2022-04-20 - Why Is Statera Biopharma (STAB) Stock Up Today?

Why Is Statera Biopharma (STAB) Stock Up Today? ... One of today's most impressive movers in the market is Stratera Biopharma (NASDAQ:STAB) on...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.4M76-10%N/A
#2
N/A7724%N/A
#3
N/A77328%N/A
#4
$10.8M77-12%N/A
#5
$16M7910%$47.9M